首页> 外文OA文献 >PND5 TREATMENT OF EARLY PARKINSONIAN PATIENTS WITH RASAGILINE OR ROPINIROLE. WHAT IS THE MOST COSTEFFECTIVE TREATMENT STRATEGY IN FINLAND?

【2h】

PND5 TREATMENT OF EARLY PARKINSONIAN PATIENTS WITH RASAGILINE OR ROPINIROLE. WHAT IS THE MOST COSTEFFECTIVE TREATMENT STRATEGY IN FINLAND?

机译：PND5雷沙吉兰或罗匹尼罗治疗早期帕金森病患者。芬兰最重要的协同治疗策略是什么？

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Armand C; Eckert L; Yrjönen T;
展开▼
作者单位

展开▼
年度 2006
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Rasagiline treatment effects on parkinsonian tremor [J] . LewM.F. International Journal of Neuroscience . 2013,第12期

机译：雷沙吉兰治疗帕金森病性震颤的作用
2. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. [J] . Hudry J, Rinne JO, Keranen T, The annals of pharmacotherapy . 2006,第4期

机译：雷沙吉兰治疗芬兰晚期帕金森氏病的成本-效用模型。
3. Economics of drug treatment: for which patients is it costeffective to lower cholesterol? [J] . Jonsson B The Lancet . 2001,第9289期

机译：药物治疗的经济性：降低胆固醇对哪些患者有效？
4. An ICT and mobile health integrated approach to optimize patients' education on hypertension and its management by physicians: The Patients Optimal Strategy of Treatment(POST) pilot study [C] . Fabio Albini, Xiaoqiu Liu, Camilla Torlasco, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：ICT和移动医疗集成的方法，可以优化患者对高血压的教育及其医生的管理：患者最佳治疗策略（POST）初步研究
5. Examining Patient's Use of, Intention to Use, and Perceived Helpfulness of Emotion Regulation Strategies in an Acceptance Based Behavioral Treatment for Bulimia Nervosa as Predictors of Treatment Outcome [D] . Parker, Megan Nicole. 2019

机译：检查患者的使用，有意使用，并在贪食症的行为治疗中对情感调节策略的乐于助听，作为治疗结果的预测因子
6. Growing body of evidence supports intrauterine insemination as firstline treatment and rejects unfounded concerns about its efficacy risks and costeffectiveness [O] . Gulam Bahadur, Roy Homburg 2019

机译：越来越多的证据支持首先进行宫腔内人工授精线治疗并拒绝对其功效风险和成本的毫无根据的担忧效力
7. PNL17 A COST-UTILITY MODEL COMPARING AZILECT® (RASAGILINE) WITH STANDARD CARE AND ENTACAPONE IN THE TREATMENT OF PARKINSONIAN PATIENTS WITH MOTOR FLUCTUATIONS UNDER LEVODOPA IN FINLAND [O] . Hudry J, Rinne J, Keränen T, 2005

机译：PNL17一种将AZILECT®（雷沙吉兰）与标准护理和恩他卡酮比较的成本效用模型，用于治疗LEVODOPA引起的帕金森氏病患者的电机波动

PND5 TREATMENT OF EARLY PARKINSONIAN PATIENTS WITH RASAGILINE OR ROPINIROLE. WHAT IS THE MOST COSTEFFECTIVE TREATMENT STRATEGY IN FINLAND?

著录项

引文网络

相似文献

相关主题

期刊订阅